Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Alfasigma S.p.a.

Aleardo Koverech

Giorgio Cavallini

Nicola Pescosolido

Giulio Biagiotti

Alberta Zallone

Claudio Cavazza

Antonio Longo

Mose Santaniello

Ashraf Virmani

Mohamed Ashraf Virmani

Stefania D'Iddio

Francesca Sardelli

Andrea Lenzi

Mariagrazia Grilli

Pier Luigi Canonico

The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.

Compounds useful for increasing neurogenesis in neural tissue

A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.

Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency

The present invention relates to a composition useful for the treatment of lipid metabolism disorders, comprising one or more of the following active ingredients: (a) extract of rice fermented with, (b) at least one omega-3 fatty acid, (c) L-carnitine or a salt thereof; and one or more of the following active ingredients: (d) at least one policosanol or a natural extract containing policosanols; (e) resveratrol or a natural extract containing resveratrol; (f) Coenzyme Q10; and (g) at least one vitamin.

Composition useful for the treatment of lipid metabolism disorders

It is described the use of L-carnitine and/or one or more alkanoyl L-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts, for the preparation of a medicament or a nutritional supplement useful for preventing or treating the Leber optic neuropathy.

Therapeutical method for the treatment of the Leber optic neuropathy

L-carnitine, acetyl L-carnitine and propionyl L-carnitine inner salts, or their pharmaceutically acceptable salts, are used in combination to treat oligoasthenoteratosperia including oligospermia, asthenospermia, and teratospermia.

Combined use of L-carnitine, acetyle L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia

The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.

Use of L-carnitine for the treatment of cardiovascular diseases

The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable.

Gel useful for the delivery of ophthalmic drugs

Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.

Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops

Erectile dysfunction is treated with a combination of propionyl L-carnitine in combination with sildenafil, apomorphine prostaglandin El, pentolamine and papaverine.

Use of alkanoyl L-carnitine for the treatment of erectile dysfunction

Use of L-carnitine or a pharmaceutically acceptable salt thereof, for the preparation of an ophthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal oedema.

Use of L-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases

The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome.

Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome

The use of acetyl L-carnitine in combination with propionyl L-carnitine and sildenafil is described for the preparation of a medicament and/or dietetic product for the treatment of erectile dysfunction secondary to all those conditions in which there is distress or iatrogenic damage of the lesser pelvis within which the neurovascular bundles of the penis run.

Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction

The use of propionyl L-carnitine in combination with acetyl L-carnitine, or one of their pharmaceutically acceptable salts, is disclosed for the preparation of a medicament, or of a nutritional supplement, for the prevention and/or treatment of the disorders of the male andropause caused by ageing or by chemical or surgical castration.

Use of carnitines for the prevention and/or treatment of disorders caused by the andropause

L-carnitine, propionyl L-carnitine and/or acetyl L-carnitine are used to prevent or treat disorders of male andropause caused by ageing or by chemical or surgical castration.

Growing community of inventors

Rome, Italy

Aleardo Koverech